A retrospective study evaluating treatment patterns and outcomes in patients receiving trastuzumab for treatment of first-line and second-line metastatic breast cancer (mBC)

被引：0
|
作者：
Lalla, D. [1 ,2 ,3 ]
Hess, G. [1 ,2 ,3 ]
Quach, D. [1 ,2 ,3 ]
Brammer, M. [1 ,2 ,3 ]
Hill, J. W. [1 ,2 ,3 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Univ Penn, SDI, Plymouth Meeting, PA USA
[3] SDI Hlth LLC, Plymouth Meeting, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12008
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Treatment patterns and survival outcomes for patients receiving second-line treatment for metastatic colorectal cancer in the USA
    Lisa M. Hess
    Zhanglin Lin Cui
    Daniel S. Mytelka
    Yimei Han
    Robert Goodloe
    William Schelman
    International Journal of Colorectal Disease, 2019, 34 : 581 - 588
  • [2] Treatment patterns and survival outcomes for patients receiving second-line treatment for metastatic colorectal cancer in the USA
    Hess, Lisa M.
    Cui, Zhanglin Lin
    Mytelka, Daniel S.
    Han, Yimei
    Goodloe, Robert
    Schelman, William
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2019, 34 (04) : 581 - 588
  • [3] Efficacy of pertuzumab in combination with trastuzumab and a taxane in first-line treatment for metastatic breast cancer (MBC): A multicenter, retrospective, observational study
    Gamucci, Teresa
    Mentuccia, Lucia
    Sperduti, Isabella
    Gelibter, Alain
    D'Onofrio, Loretta
    Cassano, Alessandra
    Iezzi, Laura
    Botticelli, Andrea
    Pizzuti, Laura
    Moscetti, Luca
    Barchiesi, Giacomo
    Scinto, Fedele
    Carbognin, Luisa
    Cursano, Maria Concetta
    Foglietta, Jennifer
    Rossi, Ernesto
    Barni, Sandro
    Graziano, Vincenzo
    Magnolfi, Emanuela
    Vici, Patrizia
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Capacitabine/trastuzumab for the first-line treatment of patients with HER2-positive metastatic breast cancer (MBC)
    Chan, A.
    Yamamoto, D.
    Bell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Capecitabine (X) in the first-line treatment of metastatic breast cancer (MBC).
    Harbeck, N.
    Kaufmann, M.
    Siedentopf, F.
    Dalivoust, P.
    Debled, M.
    Robert, N. J.
    O'Shaughnessy, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
    King, Gentry
    Ittershagen, Stacie
    He, Luyang
    Shen, Ying
    Li, Frank
    Villacorta, Reginald
    ADVANCES IN THERAPY, 2022, 39 (12) : 5433 - 5452
  • [7] Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
    Gentry King
    Stacie Ittershagen
    Luyang He
    Ying Shen
    Frank Li
    Reginald Villacorta
    Advances in Therapy, 2022, 39 : 5433 - 5452
  • [8] Gemcitabine plus cisplatin combination as second-line treatment in patients with metastatic breast cancer (MBC).
    Ajarim, D
    Ezzat, A
    Bazarbashi, S
    Rahal, M
    El Foudeh, M
    Pai, C
    Raja, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 70S - 70S
  • [9] The combination of capecitabine and vinorelbine as a first-line or a second-line treatment in inoperable breast cancer patients
    Nakagawa, T.
    Saito, M.
    Kasumi, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Phase II Multicenter Study of Docetaxel and Bevacizumab (Bev) plus /- Trastuzumab as First-Line Treatment of Patients with Metastatic Breast Cancer (MBC)
    Schwartzberg, L. S.
    Hermann, R.
    Blakely, J.
    Richey, S. S.
    Tauer, K. W.
    Childs, B. H.
    CANCER RESEARCH, 2010, 70
12345